gossypol has been researched along with Neoplasms in 44 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The article is a summary of research in China and overseas on the effect of gossypol, its compound and its derivatives in contraception and in the treatment of gynecological diseases." | 7.67 | [Gossypol and its related compounds as contraceptive drugs and drugs for gynecological diseases]. ( Wu, GP, 1988) |
| "The article is a summary of research in China and overseas on the effect of gossypol, its compound and its derivatives in contraception and in the treatment of gynecological diseases." | 3.67 | [Gossypol and its related compounds as contraceptive drugs and drugs for gynecological diseases]. ( Wu, GP, 1988) |
| " We developed and validated a sensitive HPLC assay for pharmacokinetic evaluation of gossypol." | 2.77 | A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. ( Bertino, JR; DiPaola, RS; Gounder, MK; Kong, AN; Lin, H; Stein, MN, 2012) |
| "Besides, its importance as a cancer target, various peptides and small-molecule inhibitors have been successfully designed and synthesized, yet no Mcl-1 inhibitor is approved for clinical use." | 2.72 | Development of Mcl-1 inhibitors for cancer therapy. ( Murphy, PV; Negi, A, 2021) |
| "A total of 34 patients with advanced cancer were given weekly or daily escalating doses of oral gossypol, a cottonseed-oil constituent showing evidence of antineoplastic activity in pre-clinical studies." | 2.67 | A preliminary clinical study of gossypol in advanced human cancer. ( Coombes, RC; Cunningham, DC; Ford, HT; Joseph, AE; Matlin, SA; Stein, RC, 1992) |
| "However, cancer cells frequently show upregulation of pro-survival Bcl-2 proteins and sequester activated pro-apoptotic BH3-only proteins driven by diverse cytotoxic stresses, resulting in tumor progression and chemoresistance." | 2.61 | The chemical biology of apoptosis: Revisited after 17 years. ( An, J; Huang, Z; Mao, Y; Xu, Y; Yang, S; Zhang, H, 2019) |
| "Cancer is considered as one of the most serious health problems." | 2.49 | Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. ( El-Nassan, HB, 2013) |
| "Another approach to cancer drug discovery utilizes a cancer-specific promoter as readouts of the transformed state." | 2.48 | Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. ( Bhoopathi, P; Das, SK; Dasgupta, S; Dash, R; Diaz, PW; Emdad, L; Erdogan, E; Fisher, PB; Hedvat, M; Hu, B; Kegelman, TP; Kim, K; Menezes, ME; Oyesanya, RA; Pellecchia, M; Pomper, MG; Quinn, BA; Reed, JC; Sarkar, D; Sarkar, S; Sokhi, UK; Stebbins, JL; Thomas, S; Wang, XY; Wei, J; Wu, B; Zhu, S, 2012) |
| "As far as cancer is concerned, naturally occurring compounds have been reported to prevent tumorigenesis and also to suppress the growth of established tumors." | 2.46 | Modulation of apoptosis by natural products for cancer therapy. ( Fulda, S, 2010) |
| "Most cancer cells switch their metabolism from mitochondrial oxidative phosphorylation to aerobic glycolysis to generate ATP and precursors for the biosynthesis of key macromolecules." | 1.72 | Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment. ( Bufano, M; Canettieri, G; Coluccia, A; Di Magno, L; Di Pastena, F; Frati, L; La Regina, G; Nalli, M; Ripa, S; Silvestri, R, 2022) |
| "The effects of gossypol in cancer cells were determined by western blotting, RT-qPCR, clonogenic assay, and cell viability assays." | 1.62 | A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells. ( Chang, HH; Chang, JY; Chen, HH; Chen, YT; Chuang, YJ; Kuo, CC; Tang, YC; Yao, JY, 2021) |
| "The greatest challenge in cancer therapy is posed by drug-resistant recurrence following treatment." | 1.56 | Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling. ( Jang, H; Kang, JH; Kim, HY; Kim, SY; Lee, H; Lee, JS; Lee, SH; Park, JB; Song, J; Woo, SM, 2020) |
| "But it induces limited apoptosis in cancer cells with high level of Bcl-2." | 1.48 | The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2. ( Gao, M; He, F; He, J; Huang, Y; Li, B; Li, X; Lian, J; Shi, C; Zeng, Y, 2018) |
| "Gossypol was found to retain its efficacy in v-Ha-ras-transformed NIH 3T3 cells that overexpressed P-glycoprotein (Ras-NIH 3T3/Mdr), which was similar to the efficacy observed in their parental counterparts (Ras-NIH 3T3)." | 1.39 | Defective autophagy in multidrug resistant cells may lead to growth inhibition by BH3-mimetic gossypol. ( Ahn, JH; Jang, GH; Lee, M, 2013) |
| "Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and improved therapeutic strategies." | 1.38 | Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells. ( Azmi, A; Banerjee, S; Lum, LG; Mohommad, R; Sarkar, FH; Schalk, D; Thakur, A, 2012) |
| "Gossypol treatment resulted in the decrease of anti-apoptotic genes such as Bcl-2 and Bcl-xl and an upregulation of the pro-apoptotic gene, Noxa." | 1.38 | Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. ( Liem, N; Wang, L; Wong, FY; Wong, WC; Xie, C; Yan, FL; Yong, WP, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.36) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 7 (15.91) | 29.6817 |
| 2010's | 23 (52.27) | 24.3611 |
| 2020's | 8 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Song, T | 1 |
| Li, X | 5 |
| Chang, X | 1 |
| Liang, X | 1 |
| Zhao, Y | 1 |
| Wu, G | 1 |
| Xie, S | 1 |
| Su, P | 1 |
| Wu, Z | 1 |
| Feng, Y | 1 |
| Zhang, Z | 1 |
| El-Nassan, HB | 1 |
| Rani, R | 1 |
| Kumar, V | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 2 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 2 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Wan, Y | 2 |
| Wang, J | 1 |
| Sun, F | 1 |
| Chen, M | 1 |
| Hou, X | 1 |
| Fang, H | 2 |
| Liu, T | 1 |
| Chen, C | 1 |
| Yang, S | 1 |
| Mao, Y | 1 |
| Zhang, H | 1 |
| Xu, Y | 1 |
| An, J | 1 |
| Huang, Z | 1 |
| Myers, SH | 1 |
| Ortega, JA | 1 |
| Cavalli, A | 1 |
| Negi, A | 1 |
| Murphy, PV | 1 |
| Yang, X | 2 |
| Fan, D | 1 |
| Troha, AH | 1 |
| Ahn, HM | 1 |
| Qian, K | 1 |
| Liang, B | 1 |
| Du, Y | 1 |
| Fu, H | 1 |
| Ivanov, AA | 1 |
| Di Magno, L | 1 |
| Coluccia, A | 1 |
| Bufano, M | 1 |
| Ripa, S | 1 |
| La Regina, G | 1 |
| Nalli, M | 1 |
| Di Pastena, F | 1 |
| Canettieri, G | 1 |
| Silvestri, R | 1 |
| Frati, L | 1 |
| Cai, B | 1 |
| Gong, L | 1 |
| Zhu, Y | 2 |
| Kong, L | 1 |
| Ju, X | 1 |
| Zhou, H | 1 |
| Tang, YC | 1 |
| Chang, HH | 1 |
| Chen, HH | 1 |
| Yao, JY | 1 |
| Chen, YT | 1 |
| Chuang, YJ | 1 |
| Chang, JY | 1 |
| Kuo, CC | 1 |
| Zhu, H | 1 |
| Huang, C | 1 |
| Di, J | 1 |
| Chang, Z | 1 |
| Li, K | 3 |
| Wu, D | 4 |
| Liu, H | 1 |
| Marquez, RT | 1 |
| Wu, X | 1 |
| Vadlamani, S | 1 |
| Li, S | 1 |
| Wang, Y | 2 |
| Xu, L | 2 |
| Lee, JS | 1 |
| Lee, H | 1 |
| Jang, H | 1 |
| Woo, SM | 1 |
| Park, JB | 1 |
| Lee, SH | 1 |
| Kang, JH | 1 |
| Kim, HY | 1 |
| Song, J | 1 |
| Kim, SY | 1 |
| Zeng, Y | 3 |
| Ma, J | 1 |
| Shen, S | 1 |
| Wu, Y | 1 |
| Wu, J | 1 |
| He, J | 1 |
| Li, B | 1 |
| Gao, M | 1 |
| Lian, J | 1 |
| Shi, C | 1 |
| Huang, Y | 1 |
| He, F | 1 |
| Schelman, WR | 1 |
| Mohammed, TA | 1 |
| Traynor, AM | 1 |
| Kolesar, JM | 1 |
| Marnocha, RM | 1 |
| Eickhoff, J | 1 |
| Keppen, M | 1 |
| Alberti, DB | 1 |
| Wilding, G | 1 |
| Takebe, N | 1 |
| Liu, G | 1 |
| Billard, C | 1 |
| Ignatova, M | 1 |
| Kalinov, K | 1 |
| Manolova, N | 1 |
| Toshkova, R | 1 |
| Rashkov, I | 1 |
| Alexandrov, M | 1 |
| Marzo, I | 1 |
| Naval, J | 1 |
| Azmi, AS | 1 |
| Mohammad, RM | 1 |
| Kang, MH | 1 |
| Reynolds, CP | 1 |
| Fulda, S | 1 |
| Gao, P | 1 |
| Bauvy, C | 1 |
| Souquère, S | 1 |
| Tonelli, G | 1 |
| Liu, L | 1 |
| Qiao, Z | 1 |
| Bakula, D | 1 |
| Proikas-Cezanne, T | 1 |
| Pierron, G | 1 |
| Codogno, P | 1 |
| Chen, Q | 1 |
| Mehrpour, M | 1 |
| Uzunoglu, S | 1 |
| Karaca, B | 1 |
| Atmaca, H | 1 |
| Kisim, A | 1 |
| Sezgin, C | 1 |
| Karabulut, B | 1 |
| Uslu, R | 1 |
| Bodur, C | 1 |
| Basaga, H | 1 |
| Lin, H | 1 |
| Gounder, MK | 1 |
| Bertino, JR | 1 |
| Kong, AN | 1 |
| DiPaola, RS | 1 |
| Stein, MN | 1 |
| Hedvat, M | 1 |
| Emdad, L | 1 |
| Das, SK | 1 |
| Kim, K | 1 |
| Dasgupta, S | 1 |
| Thomas, S | 1 |
| Hu, B | 1 |
| Zhu, S | 1 |
| Dash, R | 1 |
| Quinn, BA | 1 |
| Oyesanya, RA | 1 |
| Kegelman, TP | 1 |
| Sokhi, UK | 1 |
| Sarkar, S | 1 |
| Erdogan, E | 1 |
| Menezes, ME | 1 |
| Bhoopathi, P | 1 |
| Wang, XY | 1 |
| Pomper, MG | 1 |
| Wei, J | 1 |
| Wu, B | 1 |
| Stebbins, JL | 1 |
| Diaz, PW | 1 |
| Reed, JC | 1 |
| Pellecchia, M | 1 |
| Sarkar, D | 1 |
| Fisher, PB | 1 |
| Thakur, A | 1 |
| Lum, LG | 1 |
| Schalk, D | 1 |
| Azmi, A | 1 |
| Banerjee, S | 1 |
| Sarkar, FH | 1 |
| Mohommad, R | 1 |
| Wong, FY | 1 |
| Liem, N | 1 |
| Xie, C | 1 |
| Yan, FL | 1 |
| Wong, WC | 1 |
| Wang, L | 1 |
| Yong, WP | 1 |
| Ahn, JH | 1 |
| Jang, GH | 1 |
| Lee, M | 1 |
| Wu, GP | 1 |
| VERMEL, EM | 1 |
| Hockenbery, D | 1 |
| Kasten-Pisula, U | 1 |
| Windhorst, S | 1 |
| Dahm-Daphi, J | 1 |
| Mayr, G | 1 |
| Dikomey, E | 1 |
| Rodríguez-Enríquez, S | 1 |
| Gallardo-Pérez, JC | 1 |
| Avilés-Salas, A | 1 |
| Marín-Hernández, A | 1 |
| Carreño-Fuentes, L | 1 |
| Maldonado-Lagunas, V | 1 |
| Moreno-Sánchez, R | 1 |
| Sikora, MJ | 1 |
| Bauer, JA | 1 |
| Verhaegen, M | 1 |
| Belbin, TJ | 1 |
| Prystowsky, MB | 1 |
| Taylor, JC | 1 |
| Brenner, JC | 1 |
| Wang, S | 1 |
| Soengas, MS | 1 |
| Bradford, CR | 1 |
| Carey, TE | 1 |
| Hei, LS | 1 |
| Stein, RC | 1 |
| Joseph, AE | 1 |
| Matlin, SA | 1 |
| Cunningham, DC | 1 |
| Ford, HT | 1 |
| Coombes, RC | 1 |
| Benz, C | 1 |
| Hollander, C | 1 |
| Keniry, M | 1 |
| James, TL | 1 |
| Mitchell, M | 1 |
| Fishbein, L | 1 |
15 reviews available for gossypol and Neoplasms
| Article | Year |
|---|---|
Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Discovery; Humans; Kinesins; Mod | 2013 |
Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy.
Topics: Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Isoenzymes; L-Lactate Dehydrogenase; | 2016 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
The chemical biology of apoptosis: Revisited after 17 years.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Humans; Neoplasms; Proto-O | 2019 |
Synthetic Lethality through the Lens of Medicinal Chemistry.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cyclin-Dependent Kinases; DNA-Activated | 2020 |
Development of Mcl-1 inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Development; Heterocyclic Compounds; Humans; Molecul | 2021 |
Natural Product Gossypol and its Derivatives in Precision Cancer Medicine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Drug Carriers; D | 2019 |
BH3 mimetics: status of the field and new developments.
Topics: Amino Acid Motifs; Aniline Compounds; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, H | 2013 |
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
Topics: Aniline Compounds; Animals; Apoptosis; Benzamides; Binding Sites; Biphenyl Compounds; Gossypol; Huma | 2009 |
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Gossypol; Humans; | 2009 |
Modulation of apoptosis by natural products for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Clinical Trials as Topic; Gossypol; Hu | 2010 |
Bcl-2 inhibitors: emerging drugs in cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Gossypol; Humans; Indoles; Models, Biolo | 2012 |
Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Gossypol; High-Throug | 2012 |
Breaking down tumor defenses.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Gossypol; Humans; Models, Biological; Neoplasms; Pr | 2004 |
Natural non-nutrient substances in the food chain.
Topics: Abnormalities, Drug-Induced; Alkaloids; Animals; Antithyroid Agents; Arsenic Poisoning; Cadmium Pois | 1972 |
3 trials available for gossypol and Neoplasms
| Article | Year |
|---|---|
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Gossypol; | 2014 |
A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Gossypol; Humans; Limit of | 2012 |
A preliminary clinical study of gossypol in advanced human cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gossypol; Humans; Male; Middle Aged; | 1992 |
26 other studies available for gossypol and Neoplasms
| Article | Year |
|---|---|
3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
Topics: Acenaphthenes; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Drug Screening Ass | 2013 |
Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Molecul | 2015 |
Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gossypol; Humans; Molecular Docking Sim | 2017 |
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Discov | 2021 |
Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment.
Topics: Cell Line; Enzyme Inhibitors; Glycolysis; Humans; L-Lactate Dehydrogenase; Lactic Acid; Neoplasms; O | 2022 |
Identification of Gossypol Acetate as an Autophagy Modulator with Potent Anti-tumor Effect against Cancer Cells.
Topics: Acetates; AMP-Activated Protein Kinases; Apoptosis; Autophagy; Gossypol; Humans; Neoplasms | 2022 |
A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells.
Topics: Antioxidant Response Elements; Cisplatin; Etoposide; Gossypol; Humans; Neoplasms; NF-E2-Related Fact | 2021 |
Doxorubicin-Fe(III)-Gossypol Infinite Coordination Polymer@PDA:CuO
Topics: Animals; Cell Line, Tumor; Cost-Benefit Analysis; Doxorubicin; Ferric Compounds; Gossypol; Mice; Nan | 2023 |
A non-intrusive evaluation method for tumor-targeting characteristics of nanomedicines based on in vivo near-infrared fluorescence imaging.
Topics: Animals; Antineoplastic Agents; Carbocyanines; Cell Line, Tumor; Drug Carriers; Female; Fluorescent | 2019 |
Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Autophagy; Drug Resistance, Neoplasm; Drug S | 2020 |
Versatile hyaluronic acid modified AQ4N-Cu(II)-gossypol infinite coordination polymer nanoparticles: Multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Computer Systems; Copp | 2018 |
The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gossypol; Humans; Male; MAP Kinase Kina | 2018 |
Quaternized chitosan-coated nanofibrous implants loaded with gossypol prepared by electrospinning and their efficacy against Graffi myeloid tumor.
Topics: Animals; Antineoplastic Agents; Cell Death; Chitosan; Cricetinae; Drug Carriers; Drug Implants; Goss | 2014 |
Bcl-2 family members as molecular targets in cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Benzopyrans; BH3 Interacting Domain Death Agonist Protein; Biologi | 2008 |
The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells.
Topics: Androstadienes; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Be | 2010 |
Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (-/- gossypol).
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Goss | 2010 |
Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells.
Topics: Antibodies, Bispecific; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Combined Modality Thera | 2012 |
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Deoxycyt | 2012 |
Defective autophagy in multidrug resistant cells may lead to growth inhibition by BH3-mimetic gossypol.
Topics: Animals; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aut | 2013 |
[Gossypol and its related compounds as contraceptive drugs and drugs for gynecological diseases].
Topics: Abortion, Induced; Asia; Asia, Eastern; Biology; China; Contraception; Contraceptive Agents; Contrac | 1988 |
THE SEARCH FOR ANTITUMOUR SUBSTANCES OF PLANT ORIGIN.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Coumarins; Gossypol; Melanoma; Mice; Neopl | 1964 |
Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis.
Topics: Apoptosis; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; Flavonoids; Gossypol; Humans; | 2007 |
Energy metabolism transition in multi-cellular human tumor spheroids.
Topics: Adenosine Triphosphate; Animals; Cell Line, Tumor; Deoxyglucose; Energy Metabolism; Fluorescent Dyes | 2008 |
Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Cell Line; Cell Line, Tumor; Cell Survival; Dru | 2008 |
[Electron-microscopic observations on bioptic testicular tissue of cancerous patients after oral administration of gossypol (author's transl)].
Topics: Administration, Oral; Adult; Gossypol; Humans; Male; Microscopy, Electron; Middle Aged; Neoplasms; T | 1981 |
Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123.
Topics: Cell Division; Cell Line; Cell Survival; Colony-Forming Units Assay; Female; Gossypol; Hematopoietic | 1987 |